Alzheimer’s Drug Is Half Price. What Should Medicare Do?

Biogen is cutting the price of Aduhelm (aducanumab), a new treatment for Alzheimer's disease, from $56,000 to $28,000 starting in January. That could justify reducing Medicare's premium for next year, but the amount that most seniors could save is trivial. At this late date, any change in the premium amount would complicate Medicare's billing process without appreciable savings for beneficiaries.